Phenylaminopropanol derivatives and methods of their use

Details Phenylaminopropanol derivatives and methods of their use Phenylaminopropanol derivatives and methods of their use

2008-06-23

2009-12-29

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S056000, C544S059000

Reexamination Certificate

active

07638512

ABSTRACT:
The present invention is directed to phenylaminopropanol derivatives of formula I:or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

REFERENCES:
patent: 3454554 (1969-07-01), Biel et al.
patent: 4123543 (1978-10-01), Jonsson et al.
patent: 4221919 (1980-09-01), Grimova et al.
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4271160 (1981-06-01), Melloni et al.
patent: 4310524 (1982-01-01), Wiech et al.
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4826844 (1989-05-01), Husbands et al.
patent: 5502047 (1996-03-01), Kavey
patent: 5516774 (1996-05-01), Albright et al.
patent: 5648511 (1997-07-01), Ng et al.
patent: 6380155 (2002-04-01), Barazanji et al.
patent: 6703389 (2004-03-01), Wong et al.
patent: 2002/0107249 (2002-08-01), Wong et al.
patent: 2003/0008860 (2003-01-01), Bakker-Arkema et al.
patent: 2003/0069236 (2003-04-01), Vianello et al.
patent: 2004/0019101 (2004-01-01), Karlstadt et al.
patent: 2004/0143008 (2004-07-01), Deecher et al.
patent: 2004/0152710 (2004-08-01), Deecher et al.
patent: 2004/0180879 (2004-09-01), Deecher et al.
patent: 2005/0130987 (2005-06-01), Deecher et al.
patent: 2005/0143394 (2005-06-01), Mahaney et al.
patent: 2005/0143579 (2005-06-01), Trybulski et al.
patent: 2005/0148595 (2005-07-01), Mahaney
patent: 2005/0165082 (2005-07-01), Leventhal et al.
patent: 2005/0171115 (2005-08-01), Trybulski et al.
patent: 2005/0187251 (2005-08-01), Mahaney et al.
patent: 2005/0192283 (2005-09-01), Trybulski et al.
patent: 2005/0222148 (2005-10-01), Kim et al.
patent: 2556474 (2004-08-01), None
patent: 0 065 757 (1982-12-01), None
patent: 0 135 905 (1985-04-01), None
patent: 0 303 961 (1989-02-01), None
patent: 0 208 235 (1990-01-01), None
patent: 0 636 608 (1995-02-01), None
patent: 0 636 609 (1995-02-01), None
patent: 0 743 064 (1996-11-01), None
patent: 1 266 659 (2002-12-01), None
patent: 2 362 826 (2001-05-01), None
patent: 91/18602 (1991-12-01), None
patent: WO 93/15051 (1993-08-01), None
patent: WO 95/18105 (1995-07-01), None
patent: 96/05818 (1996-02-01), None
patent: WO 97/15556 (1997-05-01), None
patent: 97/35586 (1997-10-01), None
patent: WO 98/14208 (1998-04-01), None
patent: WO 98/25901 (1998-06-01), None
patent: 99/44601 (1999-09-01), None
patent: 99/55694 (1999-11-01), None
patent: WO 00/02551 (2000-01-01), None
patent: 00/59851 (2000-10-01), None
patent: WO 00/66166 (2000-11-01), None
patent: WO 00/66556 (2000-11-01), None
patent: 01/01973 (2001-01-01), None
patent: WO 01/055130 (2001-08-01), None
patent: WO 01/55134 (2001-08-01), None
patent: 01/72708 (2001-10-01), None
patent: WO 02/02520 (2002-01-01), None
patent: WO 02/22572 (2002-03-01), None
patent: 02/064543 (2002-08-01), None
patent: 02/078691 (2002-10-01), None
patent: 03/010169 (2003-02-01), None
patent: 03/037334 (2003-05-01), None
patent: 03/053426 (2003-07-01), None
patent: 03/077897 (2003-09-01), None
patent: 2004/016272 (2004-02-01), None
patent: 2004/089942 (2004-10-01), None
Acs, N. et al., “Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes?”,Endocrinology, 2001 15: 68-73.
Ahmar, M. et al., “Enzymatic resolution of methyl 2-alkyl-2-arylacetates”Tetrahedron Lett., 1989, 30(50): 7053-7056.
Ainsworth, D. P. et al., “Syntheses of Heterocyclic Compounds. Part XVI. Preparative Routes to Indoles with t-Amine Substituents in the Benzene Ring,”J. Chem. Soc. [section] C: Organic1967, 4:315-19.
Baker, W.et al., “Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement,”J. Med. Chem. 1992, 35 (10), 1722-1734.
Barberis, C. et al., “Molecular Pharmacologoy of AVP and OT Receptors and Therapeutic Potential,”Drug News Perspect, Jun. 1999, 12(5):279-292.
Barlow, D. H., “Venlafaxine for hot flushes,”Lancet, Dec. 16, 2000, 356(9247): 2025-2026.
Barton, D. et al., “Hot Flashes—Aetiology and Management,”Drugs and Aging, 2001, 18(8): 597-606.
Berendsen, H. H. G., “Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats,”European Journal of Pharmacology, 2001, 419(1): 47-54.
Berendsen, H. H. G., “Hot Flushes and serotonin,”Journal of the British Menopause Society, Mar. 2002, 8(1): 30-34.
Berendsen, H. H. G., “The role of serotonin in hot flushes,”Maturitas, 2000, 36(3): 155-164.
Brück, K. et al., “Adaptive changes in thermoregulation and their neuropharmacological basis” In: Schönbaum E. et al. (eds.).Thermoregulation: Physiology and Biochemistry, New York, Pergamon Press, (1991) pp. 255-307.
Bugle, R. C., et al., “Reduction of Azanaphthalenes by Sodium Borohydride in Trifluoroacetic Acid,”Org. Chem. 1979, 44, 1719-1720.
Bundgaard, H. (ed.),Design of Prodrugs, Elsevier (1985), Ch. 1 (pp. 1-92), Ch. 4 (pp. 157-176), Ch. 5 (pp. 177-198), and Ch. 6 (pp. 199-241).
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”J. of Pharmaceutical Sciences, Apr. 1988, 77(4):285-298.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Cacchi, S. et al., “3-Aryl-2-Unsubstituted Indoles through the Palladium-Catalysed Reaction ofo-Ethynyltrifluoroacetanilide with Aryl Iodides,”Synlett1997, 12:1363-1366.
Caliendo, G. et al., “Synthesis and Vasorelaxant Activity of New 1,4-benzoxazine Derivatives Potassium Channel Openers,”Bioorganic&Medicinal Chemistry, 2002, 10:2663-2669.
Campaigne, E. et al., “Benzo[b]thiophene Derivatives. XXVII. 5-Methoxy-6-halo-3-b-acetamidoethylbenzo[b]thiophenes, Blocked Analogs of Melatonin,”J. Heterocyclic Chem. 1983, 20, 1697-1703.
Casper, R. F. et al., “Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism,”Clinical Endocrinology, 1985, 22: 293-312.
Cavagnol, J. C. et al., “1-Alky1-1,2,3,4-tetrahydroquinoxalines,”J. Am. Chem. Soc. 1947, 69, 795-799.
Clinical Trial: “Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes”, www.clinicaltrials.gov sponsored by the National Institutes of Health, Study ID Nos. CDR0000069217; NCCTG-N99C7; NCI-P02-0204, 2003, 6 pages.
Cook, G. R. et al., “Stereochemical Consequences of the Lewis Acid-Promoted 3-Aza-Cope Rearrangement ofN-Alkyl-N-Allyl Enamines,”Tetrahedron, 1994, 50(14):4105.
de Keyzer, Y, et al., “Cloning and characterization of the human V3 pituitary vasopressin receptor,”FEBS Letters, 1994, 356:215-220.
Derick, S. et al., “[1-Deamino-4-Cyclohexylalanine] Arginine Vasopressin: A Potent and Specific Agonist for Vasopressin V1bReceptors,”Endocrinology, Dec. 2002, 143(12): 4655-4664.
Eliel, E. L.,Stereochemistry of Carbon Compounds, McGraw Hill, NY (1962) Ch. 4, pp. 46-87.
El-Subbagh, H. I. et al., “Synthesis and Antitumor Activity of Some New Substituted Quinolin-4-one and 1,7-Naphthyridin-4-one Analogs,”Arch. Pharm. 1999, 332:19-24.
Fink, G. et al., “Oestrogen and mental state,”Nature, 1996, 383(6598): 306.
Folny, V. et al., “Pancreatic vasopressin V1breceptors: characterization in In-R1-G9 cells and lo

Affiliated with

Also associated with

Rating

Phenylaminopropanol derivatives and methods of their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phenylaminopropanol derivatives and methods of their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylaminopropanol derivatives and methods of their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4062903